A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression

Yun Wang,1 Xiaohua Liu,2,3 Daihui Peng,2 Yan Wu,2 Yun’ai Su,4 Jia Xu,5 Xiancang Ma,6 Yi Li,7 Jianfei Shi,8 Xiaojing Cheng,9 Han Rong,10 Yiru Fang1,3,11 1Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China;...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Wang Y, Liu X, Peng D, Wu Y, Su Y, Xu J, Ma X, Li Y, Shi J, Cheng X, Rong H, Fang Y
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	major depressive disorder melancholic depression fluoxetine bupropion cognitive behavioral therapy brain stimulation. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/42ed137816a64fc3939b0b8f442d6ce9
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:42ed137816a64fc3939b0b8f442d6ce9
record_format	dspace
institution	DOAJ
collection	DOAJ
language	EN
topic	major depressive disorder melancholic depression fluoxetine bupropion cognitive behavioral therapy brain stimulation. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	major depressive disorder melancholic depression fluoxetine bupropion cognitive behavioral therapy brain stimulation. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Wang Y Liu X Peng D Wu Y Su Y Xu J Ma X Li Y Shi J Cheng X Rong H Fang Y A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression
description	Yun Wang,1 Xiaohua Liu,2,3 Daihui Peng,2 Yan Wu,2 Yun’ai Su,4 Jia Xu,5 Xiancang Ma,6 Yi Li,7 Jianfei Shi,8 Xiaojing Cheng,9 Han Rong,10 Yiru Fang1,3,11 1Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 2Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 3Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 4Department of Psychiatry, Peking University Sixth Hospital, Peking, People’s Republic of China; 5Department of Psychiatry, Harbin First Specific Hospital, Harbin, People’s Republic of China; 6Department of Psychiatry, The First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an, People’s Republic of China; 7Department of Psychiatry, Wuhan Mental Health Center, Wuhan, People’s Republic of China; 8Department of Psychiatry, Hangzhou Seventh People’s Hospital, Hangzhou, People’s Republic of China; 9Department of Psychiatry, Shandong Mental Health Center, Shandong, People’s Republic of China; 10Department of Psychiatry, Shenzhen Kangning Hospital, Shenzhen, People’s Republic of China; 11CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai, People’s Republic of ChinaCorrespondence: Daihui Peng; Yiru Fang Email pdhsh@126.com; yirufang@aliyun.comBackground: Fluoxetine, bupropion, cognitive behavioral therapy (CBT), and physical therapies (modified electroconvulsive treatment or repetitive transcranial magnetic stimulation) can be used to manage melancholic depression.Objective: To compare the efficacy and safety of various treatments in patients with melancholic depression.Methods: This was a preliminary multicenter randomized controlled trial that included patients with depression in their first or recurrent acute episode between September 2016 and June 2019, and randomized to fluoxetine, fluoxetine+CBT, fluoxetine+bupropion, and fluoxetine+bupropion+brain stimulation. The primary endpoint was the decrease in the 17-item Hamilton Depression Rating Scale (17-HDRS). The secondary endpoint included the scores from the Quick Inventory of Depressive Symptomatology (QIDS-SR), QOL-6, and safety. Adverse events (AEs) were monitored. The follow-ups were performed at the end of the 0th, 2nd, 4th, 6th, 8th, and 12th weeks of treatment.Results: Finally, 113 patients were included in the analyses: fluoxetine (n=37), fluoxetine+CBT (n=27), fluoxetine+bupropion (n=34), and fluoxetine+bupropion+brain stimulation (n=15). The 17-HDRS and QIDS-SR scores decreased in all four groups (all P< 0.05). There were no differences in the 17-HDRS scores among the four groups at the end of treatment (P=0.779), except for fluoxetine alone showing a better response regarding self-consciousness than fluoxetine+bupropion. The QOL-6 scores increased in all four groups. The occurrence of AEs among the four groups showed no significant difference (P=0.053).Conclusion: This preliminary trial suggests that all four interventions (fluoxetine, fluoxetine+CBT, fluoxetine+bupropion, and fluoxetine+bupropion+brain stimulation) achieved similar response and remission rates in patients with melancholic depression, but that fluoxetine had a better effect on self-consciousness than fluoxetine+bupropion. The safety profile was manageable.Keywords: major depressive disorder, melancholic depression, fluoxetine, bupropion, cognitive behavioral therapy, brain stimulation
format	article
author	Wang Y Liu X Peng D Wu Y Su Y Xu J Ma X Li Y Shi J Cheng X Rong H Fang Y
author_facet	Wang Y Liu X Peng D Wu Y Su Y Xu J Ma X Li Y Shi J Cheng X Rong H Fang Y
author_sort	Wang Y
title	A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression
title_short	A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression
title_full	A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression
title_fullStr	A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression
title_full_unstemmed	A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression
title_sort	preliminary randomized controlled trial of different treatment regimens for melancholic depression
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/42ed137816a64fc3939b0b8f442d6ce9
work_keys_str_mv	AT wangy apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT liux apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT pengd apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT wuy apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT suy apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT xuj apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT max apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT liy apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT shij apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT chengx apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT rongh apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT fangy apreliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT wangy preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT liux preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT pengd preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT wuy preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT suy preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT xuj preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT max preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT liy preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT shij preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT chengx preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT rongh preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression AT fangy preliminaryrandomizedcontrolledtrialofdifferenttreatmentregimensformelancholicdepression
_version_	1718383510310354944
spelling	oai:doaj.org-article:42ed137816a64fc3939b0b8f442d6ce92021-12-02T16:43:36ZA Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression1178-2021https://doaj.org/article/42ed137816a64fc3939b0b8f442d6ce92021-07-01T00:00:00Zhttps://www.dovepress.com/a-preliminary-randomized-controlled-trial-of-different-treatment-regim-peer-reviewed-fulltext-article-NDThttps://doaj.org/toc/1178-2021Yun Wang,1 Xiaohua Liu,2,3 Daihui Peng,2 Yan Wu,2 Yun’ai Su,4 Jia Xu,5 Xiancang Ma,6 Yi Li,7 Jianfei Shi,8 Xiaojing Cheng,9 Han Rong,10 Yiru Fang1,3,11 1Division of Mood Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 2Department of Psychiatry, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 3Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China; 4Department of Psychiatry, Peking University Sixth Hospital, Peking, People’s Republic of China; 5Department of Psychiatry, Harbin First Specific Hospital, Harbin, People’s Republic of China; 6Department of Psychiatry, The First Affiliated Hospital of Xi’an Jiao Tong University, Xi’an, People’s Republic of China; 7Department of Psychiatry, Wuhan Mental Health Center, Wuhan, People’s Republic of China; 8Department of Psychiatry, Hangzhou Seventh People’s Hospital, Hangzhou, People’s Republic of China; 9Department of Psychiatry, Shandong Mental Health Center, Shandong, People’s Republic of China; 10Department of Psychiatry, Shenzhen Kangning Hospital, Shenzhen, People’s Republic of China; 11CAS Center for Excellence in Brain Science and Intelligence Technology, Shanghai, People’s Republic of ChinaCorrespondence: Daihui Peng; Yiru Fang Email pdhsh@126.com; yirufang@aliyun.comBackground: Fluoxetine, bupropion, cognitive behavioral therapy (CBT), and physical therapies (modified electroconvulsive treatment or repetitive transcranial magnetic stimulation) can be used to manage melancholic depression.Objective: To compare the efficacy and safety of various treatments in patients with melancholic depression.Methods: This was a preliminary multicenter randomized controlled trial that included patients with depression in their first or recurrent acute episode between September 2016 and June 2019, and randomized to fluoxetine, fluoxetine+CBT, fluoxetine+bupropion, and fluoxetine+bupropion+brain stimulation. The primary endpoint was the decrease in the 17-item Hamilton Depression Rating Scale (17-HDRS). The secondary endpoint included the scores from the Quick Inventory of Depressive Symptomatology (QIDS-SR), QOL-6, and safety. Adverse events (AEs) were monitored. The follow-ups were performed at the end of the 0th, 2nd, 4th, 6th, 8th, and 12th weeks of treatment.Results: Finally, 113 patients were included in the analyses: fluoxetine (n=37), fluoxetine+CBT (n=27), fluoxetine+bupropion (n=34), and fluoxetine+bupropion+brain stimulation (n=15). The 17-HDRS and QIDS-SR scores decreased in all four groups (all P< 0.05). There were no differences in the 17-HDRS scores among the four groups at the end of treatment (P=0.779), except for fluoxetine alone showing a better response regarding self-consciousness than fluoxetine+bupropion. The QOL-6 scores increased in all four groups. The occurrence of AEs among the four groups showed no significant difference (P=0.053).Conclusion: This preliminary trial suggests that all four interventions (fluoxetine, fluoxetine+CBT, fluoxetine+bupropion, and fluoxetine+bupropion+brain stimulation) achieved similar response and remission rates in patients with melancholic depression, but that fluoxetine had a better effect on self-consciousness than fluoxetine+bupropion. The safety profile was manageable.Keywords: major depressive disorder, melancholic depression, fluoxetine, bupropion, cognitive behavioral therapy, brain stimulationWang YLiu XPeng DWu YSu YXu JMa XLi YShi JCheng XRong HFang YDove Medical Pressarticlemajor depressive disordermelancholic depressionfluoxetinebupropioncognitive behavioral therapybrain stimulation.Neurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 17, Pp 2441-2449 (2021)

A Preliminary Randomized Controlled Trial of Different Treatment Regimens for Melancholic Depression

Ejemplares similares